13F Pro quality score
Rank #2,812 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Reported revenue, net income and operating margin by fiscal year, from Endovia Health Sciences, Inc.'s annual filings on SEC EDGAR.
| Period | Form | Revenue | Net income | Op. marginOperating margin |
|---|---|---|---|---|
| FY 2025 | 10-K | $73.1K | $-25.2M | — |
| FY 2024 | 10-K | $801.3K | $-23.8M | — |
| FY 2023 | 10-K | $18.9M | $-21.0M | -81.1% |
| FY 2022 | 10-K | $18.1M | $-21.7M | -118.3% |
| FY 2021 | 10-K | $11.3M | $-29.1M | — |
| FY 2020 | 10-K | $2.3M | $-28.7M | — |
Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
Endovia Health Sciences, Inc. (EDVA) stock profile, AI quality score, and SEC EDGAR financial data, a Consumer Staples sector company. 13F Pro's AI-powered ranking engine scores EDVA at 15.6/100 on a composite quality score built from its SEC filings, placing it at rank #2,812 of 2,925 stocks — the bottom half of the AI-ranked universe. Top institutional holders of EDVA by reported 13-F value include JANE STREET GROUP, Phraction Management, Summit Trail Advisors, based on the most recent SEC filings. EDVA trades on the NYSE exchange and files with the SEC under CIK 1553788. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EDVA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Endovia Health Sciences, Inc. directly from SEC EDGAR.
Financials through the period ended SEC EDGAR: CIK 1553788 →